Please join Foley and Charles River Associates for a round table discussion with Zack Fang, member of the Chinese State Counsel Health Care Reform Expert Advisory Committee, and fellow panelists, to discuss:
- Myths about the Chinese health care system
- Competition and collaboration with local companies
- Opening China’s hospital market
- Price and market access issues faced by multinational pharmaceutical companies in China
Introduction
- Adria Warren, Senior Counsel, Foley & Lardner LLP
Moderator
- Dr. Elizabeth Xiao-Ru Wang, Principal, Charles River Associates
Panelists
- Dr. Jim Ewing, Partner, Foley & Lardner LLP
- Dr. Zack Fang, member of the Chinese State Counsel Health Care Reform Expert Advisory Committee
- Xiaolin Zhou, Partner, Jun He Law Offices
There is no cost to participate in this program; however, pre-registration is required. For additional information, please contact Delia Dai at [email protected].
People
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.